← Back
SiliconANGLE AI

AI drug discovery startup Basecamp Research raises $140M

•
#nvidia
AI drug discovery startup Basecamp Research raises $140M
Level:Intermediate
For:AI Engineers
✦TL;DR

Basecamp Research announced a $140 million Series C funding round led by S32, a fund tied to Google co‑founder Bill Maris. The round also attracted more than a dozen investors, including Nvidia Corp. and the Anthology Fund. This sizable capital injection underscores strong investor confidence in AI‑driven drug discovery platforms, enabling the startup to accelerate its computational chemistry pipelines.

⚡ Key Takeaways

  • Funding amount: $140 million.
  • Round type: Series C, led by S32.
  • Notable investors: Nvidia Corp. and the Anthology Fund.
  • Strategic implication: capital will support scaling of AI models for molecular design.
💡 Why It Matters

The influx of capital allows Basecamp Research to expand its AI‑based drug discovery infrastructure, potentially shortening the timeline from target identification to candidate selection for pharmaceutical partners.

✅ Practical Steps

  1. Apply the concepts from this article to your own system design.

Want the full story? Read the original article.

Read on SiliconANGLE AI ↗

More like this

NVIDIA and Microsoft Expand Accelerated Computing From Azure to Windows PCs

NVIDIA Blog•#compute

Into the Omniverse: How Developers Turn Ideas Into Simulations With Frontier AI Agents

NVIDIA Blog•#agents

How the World’s Most Advanced AI Infrastructure Supply Chain Invents the Future

NVIDIA Blog•#nvidia

Lambda Boosts AI Factory Resiliency and Efficiency With NVIDIA Photonics

NVIDIA Blog•#compute

EXPLORE AI NEWS

Daily hand-picked stories on LLMs, RAG, agents and production AI — curated for engineers who ship.

BROWSE NEWS

GET THE WEEKLY DIGEST

Join engineers getting the Monday signal-over-noise AI breakdown. No spam, unsubscribe anytime.

LEARN AI ENGINEERING

Curated courses, research papers, repos and tutorials built for engineers leveling up in AI.

START LEARNING